The case for targeting latent and lytic Epstein-Barr virus infection in multiple sclerosis - Top-Institutions - MDSpire

The case for targeting latent and lytic Epstein-Barr virus infection in multiple sclerosis

  • By

  • Gavin Giovannoni

  • Louisa James

  • Adekunle A Adeniran

  • Julian Gold

  • Lawrence S Young

  • David L Selwood

  • David Baker

  • Ruth Dobson

  • May 6, 2025

  • 0 min

Share

Top Institutions in Neurology

Brief introduction explaining scope and methodology.

  • #1

    National Institute of Neurological Disorders and Stroke (NINDS), NIH
    National Institute of Neurological Disorders and Stroke (NINDS), NIH

    Bethesda, MD

    Key Differentiators

    • Neurology
    • Neuroimmunology
    • Virology

  • #2

    Johns Hopkins University School of Medicine
    Johns Hopkins University School of Medicine

    Baltimore, MD

    Key Differentiators

    • Neurology
    • Immunology
    • Virology

  • #3

    University of California, San Francisco (UCSF) School of Medicine
    University of California, San Francisco (UCSF) School of Medicine

    San Francisco, CA

    Key Differentiators

    • Neurology
    • Neuroimmunology
    • Infectious Diseases

  • #4

    University of Oxford, Nuffield Department of Clinical Neurosciences
    University of Oxford, Nuffield Department of Clinical Neurosciences

    Oxford, Oxfordshire

    Key Differentiators

    • Neurology
    • Immunology
    • Virology

  • #5

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Neurology
    • Neuroimmunology
    • Clinical Research

Original Source(s)

The case for targeting latent and lytic Epstein-Barr virus infection in multiple sclerosis

  • by Gavin Giovannoni, Louisa James, Adekunle A Adeniran, Julian Gold, Lawrence S Young, David L Selwood, David Baker, Ruth Dobson

  • May 6, 2025

Related Content

The quality of life in Ecuadorian patients with multiple sclerosis and neuromyelitis optica spectrum disorder and their association with anxiety, depression, fatigue, and disability

Correction: Improving the Endocannabinoid System for Addressing Residual Disease in Multiple Sclerosis Without Relapses

FDA Reshapes Drug Testing Approach

The agency outlined early regulatory actions supporting nonanimal methods, including draft guidance, artificial intelligence tools, and expanded use of human-relevant data models.